SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,935,352, assigned to Vical and the University of Washington, covering DNA vaccines for herpes simplex virus type 2 (HSV-2). Prior patents from this collaboration are U.S. Patent Nos. 7,628,993 and 7,879,339. Vical is collaborating with the University of Washington School of Medicine and the Sealy Center for Vaccine Development, both centers of excellence in herpes virus research, under a previously disclosed grant on the preclinical development of an HSV-2 vaccine. The initial focus will be for people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral shedding and transmission. The vaccine will be evaluated with Vical's Vaxfectin® adjuvant.
